

Morgan Stanley Key Information Document

Purpose

This document provides you with key information about this product. It is not marketing material. The information is required by the Packaged Retail and Insurance-Based Investment Products Regulation ("PRIIPs") to help you understand the key features, risks, costs and potential gains and losses of this product and to help you compare it with other products covered by PRIIPs.

Product

| | |
|---|---|
| Product name | Autocallable Barrier Worst-of Note Linked to a Basket of Indices |
| Product identifier | ISIN: XS2477011097 |
| PRIIP manufacturer | Morgan Stanley & Co. International plc (http://sp.morganstanley.com/). The product issuer is Morgan Stanley BV with a guarantee by Morgan Stanley. |
| Telephone number | +44-20-7425-8000 |
| Competent authority of the PRIIP manufacturer | Morgan Stanley & Co. International plc is not established in the European Union (EU) or supervised by an EU competent authority. It is authorised by the U.K. Prudential Regulation Authority and regulated by the U.K. Financial Conduct Authority and U.K. Prudential Regulation Authority. |
| Date and time of production | 19 May 2022 17:03 Luxembourg (city) local time |

You are about to purchase a product that is not simple and may be difficult to understand.

1. What is this product?

| | |
|------------|---|
| Type | English law governed notes |
| Objectives | <p>The product is designed to provide a return in the form of a cash payment on termination of the product. The timing and amount of this payment will depend on the performance of the underlyings. The product has a fixed term and will terminate on the maturity date, unless terminated early. If, at maturity, the final reference level of the worst performing underlying has fallen below its barrier level, the product may return less than the product notional amount or even zero.</p> <p><u>Early termination following an autocall:</u> The product will terminate prior to the maturity date if, on any autocall observation date, the reference level of the worst performing underlying is at or above its autocall barrier level. On any such early termination, you will on the immediately following autocall payment date receive a cash payment equal to the applicable autocall payment. The relevant dates and autocall payments are shown in the table(s) below.</p> |

| Autocall observation dates | Autocall payment dates | Autocall payments |
|----------------------------|------------------------|-------------------|
| 22 June 2023 | 29 June 2023 | USD 1,135.00 |
| 22 December 2023 | 2 January 2024 | USD 1,202.50 |
| 24 June 2024 | 1 July 2024 | USD 1,270.00 |
| 23 December 2024 | 31 December 2024 | USD 1,337.50 |
| 23 June 2025 | 30 June 2025 | USD 1,405.00 |
| 22 December 2025 | 30 December 2025 | USD 1,472.50 |
| 22 June 2026 | 29 June 2026 | USD 1,540.00 |
| 22 December 2026 | 30 December 2026 | USD 1,607.50 |
| 22 June 2027 | Maturity date | USD 1,675.00 |

Termination on the maturity date: If the product has not terminated early, on the **maturity date** you will receive:

1. if the **final reference level** of the **worst performing underlying** is at or above its **barrier level**, a cash payment equal to USD 1,000.00; or
2. if the **final reference level** of the **worst performing underlying** is below its **barrier level**, a cash payment directly linked to the performance of the **worst performing underlying**. The cash payment will equal (i) the **product notional amount** multiplied by (ii) (A) the **final reference level** of the **worst performing underlying** divided by (B) its **strike level**.

Under the product terms, certain dates specified above and below will be adjusted if the respective date is either not a business day or not a trading day (as applicable). Any adjustments may affect the return, if any, you receive.

The product terms also provide that if certain exceptional events occur (1) adjustments may be made to the product and/or (2) the product issuer may terminate the product early. These events are specified in the product terms and principally relate to the **underlyings**, the product and the product issuer. The return (if any) you receive on such early termination is likely to be different from the scenarios described above and may be less than the amount you invested.

You do not have any entitlement to a dividend from any of the **underlyings** and you have no right to any further entitlement resulting from any such **underlying** (e.g., voting rights).

| | | | |
|-------------------------|---|-------------------|---|
| Underlyings | EURO STOXX 50 INDEX (Price return index) (SX5E; ISIN: EU0009658145; Bloomberg: SX5E Index), NASDAQ 100 INDEX (Price return index) (NDX; ISIN: US6311011026; Bloomberg: NDX Index) and NIKKEI 225 INDEX (Price return index) (NKY; ISIN: JP9010C00002; Bloomberg: NKY Index) | Barrier level | 65.00% of the initial reference level |
| Asset class | Equity | Reference level | The closing level of an underlying as per the relevant reference source |
| Product notional amount | USD 1,000.00 | Reference sources | <ul style="list-style-type: none">• SX5E: STOXX• NDX: NASDAQ Global Market• NKY: Nikkei |

| | | | |
|-------------------------|---|-----------------------------|--|
| Issue price | 100.00% of the product notional amount | Final reference level | The reference level on the final valuation date |
| Product currency | U.S. Dollar (USD) | Initial valuation date | 22 June 2022 |
| Underlying currencies | • SX5E: Euro (EUR) • NDX: USD • NKY: Japanese Yen (JPY) | Final valuation date | 22 June 2027 |
| Issue date | 29 June 2022 | Maturity date / term | 29 June 2027 |
| Initial reference level | The reference level on the initial valuation date | Autocall barrier level | 100.00% of the initial reference level |
| Strike level | 100.00% of the initial reference level | Worst performing underlying | For purposes of the payment at maturity: The underlying with the worst performance between the initial reference level and the final reference level For all other purposes: For a given date, the underlying with the worst performance between the initial reference level and the relevant reference level |


Intended retail investor The product is intended to be offered to retail investors who fulfil all of the criteria below:

1. they have the ability to make an informed investment decision through sufficient knowledge and understanding of the product and its specific risks and rewards, either independently or through professional advice, and they may have experience of investing in and/or holding a number of similar products providing a similar market exposure;
2. they expect the movement in the underlyings to perform in a way that generates a favourable return, have an investment horizon of the recommended holding period specified below and understand that the product may terminate early;
3. they accept the risk that the issuer or guarantor could fail to pay or perform its obligations under the product and they are able to bear a total loss of their investment; and
4. they are willing to accept a level of risk to achieve potential returns that is consistent with the summary risk indicator shown below.

The product is not intended to be offered to retail clients who do not fulfil these criteria.

2. What are the risks and what could I get in return?

Risk indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class. This rates the potential losses from future performance at a medium-high level, and poor market conditions are unlikely to impact our capacity to pay you.

To the extent the currency of the country in which you purchase this product or your account currency differs from the product currency, please be aware of currency risk. You will receive payments in a different currency so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

This product does not include any protection from future market performance so you could lose some or all of your investment.

For detailed information about all risks relating to the product please refer to the risk sections of the prospectus and any supplements thereto as specified in the section "7. Other relevant information" below.

Performance scenarios Market developments in the future cannot be accurately predicted. The scenarios shown are only an indication of some of the possible outcomes based on recent returns. Actual returns could be lower.

| Investment: USD 10,000 | | | | |
|------------------------------|--|-------------------------|-------------------------|------------------------------|
| Scenarios | 1 year | 3 years | 5 years | (Recommended holding period) |
| Stress scenario | What you might get back after costs Average return each year | USD 3,303.59 -66.96% | USD 2,781.36 -34.72% | USD 1,966.12 -27.77% |
| Unfavourable scenario | What you might get back after costs Average return each year | USD 5,501.60 -44.98% | USD 4,587.05 -22.88% | USD 3,584.78 -18.55% |
| Moderate scenario | What you might get back after costs Average return each year | USD 7,538.92 -24.61% | USD 7,805.66 -7.93% | USD 10,000.00 0.00% |
| Favourable scenario | What you might get back after costs Average return each year | USD 11,252.48 12.52% | USD 12,065.50 6.46% | USD 12,700.00 4.90% |

This table shows the money you could get back over the next 5 years as well as the annualized return calculated on a compounded basis under different scenarios, assuming that you invest USD 10,000.

The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products. The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and are not an

exact indicator. What you get will vary depending on how the market performs and how long you keep the product. The stress scenario shows what you might get back in extreme market circumstances, and it does not take into account the situation where we are not able to pay you. In addition, you should note that the results shown for the intermediate holding periods do not reflect estimates of the product's future value. You should therefore not base your investment decision on the results shown for these interim holding periods.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

3. What happens if Morgan Stanley BV is unable to pay out?

You are exposed to the risk that the issuer or guarantor might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or an official directive for resolution action. This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not a deposit and as such is not covered by any deposit protection scheme.

4. What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for three different holding periods. They include potential early exit penalties. The figures assume you invest USD 10,000. The figures are estimates and may change in the future.

Costs over time

| Investment: USD 10,000 | | | |
|--|-----------------------------|------------------------------|---|
| Scenarios | If you cash in after 1 year | If you cash in after 3 years | If you cash in at the end of the recommended holding period |
| Total costs | USD 1,137.82 | USD 1,137.82 | USD 1,087.82 |
| Impact on return (RIY) per year | 9.76307% | 3.80719% | 2.33006% |

The costs shown in the table above represent how much the expected costs of the product would affect your return, assuming the product performs in line with the moderate performance scenario.

The person selling you or advising you about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.

Composition of costs

The table below shows:

- The impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period.
- The meaning of the different cost categories.

The table shows the impact on return per year.

| | | | |
|---------------|---------------------|----------|---|
| One-off costs | Entry costs | 2.33006% | The impact of the costs already included in the price. |
| | Exit costs | 0.00% | The impact of the costs of exiting your investment when it matures. |
| Ongoing costs | Other ongoing costs | 0.00% | The impact of the costs that we take each year for managing your investments. |

The costs shown in the table above represent the split of the reduction in yield shown in the costs over time table at the end of the recommended holding period. The split of the actual estimated costs of the product as a percentage of the **product notional amount** is estimated to be as follows: entry costs: 10.87824% and exit costs: 0.00%.

5. How long should I hold it and can I take money out early?

Recommended holding period: 5 years

The product aims to provide you with the return described under "1. What is this product?" above. However, this only applies if the product is held to maturity. It is therefore recommended that the product is held until 29 June 2027 (maturity).

The product does not guarantee the possibility to disinvest other than by selling the product either (1) through the exchange (if the product is exchange traded) or (2) off-exchange, where an offer for such product exists. No fees or penalties will be charged by the issuer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

| | | | |
|------------------------|---|-----------------|------------|
| Exchange listing | Irish Stock Exchange - Global Exchange Market | Price quotation | Percentage |
| Smallest tradable unit | USD 1,000.00 | | |

In volatile or unusual market conditions, or in the event of technical faults/disruptions, the purchase and/or sale of the product can be temporarily hindered and/or suspended and may not be possible at all.

6. How can I complain?

Any complaint regarding the conduct of the person advising on, or selling, the product can be submitted directly to that person.

Any complaint regarding the product or the conduct of the manufacturer of this product can be submitted in writing at the following address: Morgan Stanley & Co. International plc, 25 Cabot Square, London E14 4QA, United Kingdom, by email to: rspcomplaints@morganstanley.com. Please see also <http://sp.morganstanley.com/>. Complaints should include the name of the product, ISIN and reason for the complaint.

7. Other relevant information

The information contained in this Key Information Document does not constitute a recommendation to buy or sell the product and is no substitute for individual consultation with your bank or advisor.

The product is not in any way sponsored, sold or promoted by any relevant stock market, relevant index, related exchange or index sponsor. Further information in respect of the index is available from the index administrator.

The offering of this product has not been registered under the U.S. Securities Act of 1933. This product may not be offered or sold, directly or indirectly, in the United States of America or to U.S. persons. The term "U.S. person" is defined in Regulation S under the U.S. Securities Act of 1933, as amended.

Any additional documentation in relation to the product, in particular, the issuance programme documentation, any supplements thereto and the product terms are available free of charge from Morgan Stanley & Co. International plc, 25 Cabot Square, London E14 4QA, United Kingdom.